5PSQ-010 Benefits provided by recombinant long half-life coagulation factors in patients with severe haemophilia ‘A’ in prophylaxis

Abstract

DOACs, renal function, drugs associated with bleeding and comorbidities. Results Conclusion and relevance The population showed a prevalence for UGIH and ICH of 1% from ES admissions, and 4.5% of these were associated with DOAC use. Only in one case was the posology inappropriate and in all patients the indication was suitable. It was observed that comorbidities may affect bleeding risk more than drugs although we should not underestimate the importance of concomitant drugs.